中国药物经济学2024，Vol.19Issue(4)：76-80,5.DOI:10.12010/j.issn.1673-5846.2024.04.014
启膈散加减方联合TS化疗方案治疗中晚期食管鳞癌的临床疗效及安全性
Clinical Efficacy and Safety of Qige Pulvis Plus Minus Formula combined with TS Chemotherapy in the Treatment of Middle and Advanced Esophageal Squamous Carcinoma
摘要
Abstract
Objective To explore the clinical efficacy and safety of Qige pulvis plus minus formula combined with TS chemotherapy in the treatment of advanced esophageal squamous cell carcinoma(ESCC).Methods Eighty patients with advanced ESCC treated and treated in Yangzhou Hospital of Traditional Chinese Medicine from January 2019 to June 2022 were selected as the study objects,and were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with TS chemotherapy,and the observation group was treated with Qige pulvis plus minus formula on the basis of the control group.The clinical efficacy,TCM syndrome score,serum tumor marker level and adverse reactions were compared between the two groups.Results The effective rate of the observation group was 90.0%,which was significantly higher than that of the control group(72.5%)(P＜0.05).After treatment,the scores of dysphagia,pain,hoarseness,loss of appetite,emaciation,and saliva vomiting in the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P＜0.05).After treatment,serum squamous cell carcinoma antigen(SSCAg)level in 2 groups was lower than before treatment,and serum SSCAg level in observation group was lower than control group,the difference was statistically significant(P＜0.05).There was no significant difference in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)and carbohydrate antigen 724(CA724)between the two groups(P＞0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P＞0.05).Conclusion Qige pulvis plus minus formula combined with TS chemotherapy has significant clinical efficacy in the treatment of ESCC,and can effectively improve clinical symptoms with high safety.关键词
食管鳞癌/联合治疗/启膈散/化疗Key words
Esophageal squamous carcinoma/Combination therapy/Qige pulvis/Chemotherapy分类
医药卫生引用本文复制引用
冒德芳,邱美林,姜晓敏,金凤..启膈散加减方联合TS化疗方案治疗中晚期食管鳞癌的临床疗效及安全性[J].中国药物经济学,2024,19(4):76-80,5.基金项目
国家自然科学基金青年项目(81903850) （81903850）
江苏省中医药管理局项目(YB201992) （YB201992）
